An update on the work of the Oncology Health Economic Modeling Working Group conducting a systematic literature review (SLR) of health utilities, resource use and costs in post-progression/post-response in advanced oncology indications (primary studies and economic evaluations). The objective of the SLR is (i) to assess current gaps, data quality issues and other challenges in eliciting/collecting, analyzing and implementing post-progression/post-response data inputs in economic evaluations and (ii) to make recommendations in collaboration with clinicians, payers, and patient representatives, for future research and approaches to overcoming these challenges. The methods and preliminary results (selection of articles based on titles and abstracts) were presented at the ISPOR 22nd Annual International Meeting in May 2017. The forum will present the final study selection results and the preliminary findings based on extracted data. Data availability and quality will be assessed and data gaps and limitations will be identified according to indications, countries and methods for elicitation and analyses. Methods used for implementation of utility, costs and resource use data in economic evaluations will also be described, and inconsistencies between model/health technology assessment requirements and data availability and quality will be discussed. The predominant partitioned survival models assume that utilities and costs are dependent mainly on progression status. The availability of data to support and/or contradict this assumption will be assessed. The audience will be invited to comment and provide feedback on the project. The presentation may be of interest to anyone involved in producing or using results of cost-effectiveness models of advanced oncology treatments, including health economists, members of health technology assessment bodies and manufacturers.